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other organs and disease relapse rate. While LPSP is associ-
ated with elevation of titers of nonspecific autoantibodies 
and serum IgG4 levels, IDCP does not have definitive sero-
logic autoimmune markers. All experts agreed that the clini-
cal phenotypes associated with LPSP and IDCP should be 
nosologically distinguished; however, their terminology was 
controversial. While most experts agreed that the entities 
should be referred to as type 1 and type 2 AIP, respectively, 
others had concerns regarding use of the term ‘autoimmune’ 
to describe IDCP.  Copyright © 2011 S. Karger AG, Basel and IAP
 Background
 A form of idiopathic chronic pancreatitis suspected to 
be due to an autoimmune process was first described by 
Sarles et al.  [1] in 1961. In 1991, Kawaguchi et al.  [2] de-
scribed ‘an unusual lymphoplasmacytic sclerosing in-
flammatory disease involving the total pancreas, com-
mon bile duct, gallbladder, and, in one patient, the lip’ in 
2 patients who presented with a mass-like enlargement of 
the pancreatic head. Histopathologic characteristics in-
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 Abstract
 Autoimmune pancreatitis (AIP) has been extensively report-
ed from Japan, Europe and the USA. While the descriptions 
of AIP from Japan have predominantly been based on the 
presence of a distinct clinical phenotype, reports from Eu-
rope and the USA describe at least 2 histopathologic pat-
terns in patients diagnosed with AIP, namely lymphoplas-
macytic sclerosing pancreatitis (LPSP) and idiopathic duct-
centric pancreatitis (IDCP) or granulocytic epithelial lesion-
positive pancreatitis. While the 2 entities share common 
histopathologic features (periductal lymphoplasmacytic in-
filtration and peculiar periductal fibrosis), expert patholo-
gists can accurately distinguish them on the basis of other 
unique histopathologic features. Clinically, the 2 entities 
have a similar presentation (obstructive jaundice/pancreatic 
mass and a dramatic response to steroids), but they differ 
significantly in their demography, serology, involvement of 
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cluded diffuse lymphoplasmacytic infiltration, marked 
interstitial fibrosis, acinar atrophy and obliterative phle-
bitis of the pancreatic and portal veins. They called the 
condition lymphoplasmacytic sclerosing pancreatitis 
(LPSP) with cholangitis  [2] . In 1995, Yoshida et al.  [3] de-
scribed a 68-year-old woman with steroid-responsive dis-
ease presenting with obstructive jaundice, a diffusely en-
larged pancreas, an irregularly narrowed pancreatic duct, 
hypergammaglobulinemia and elevated autoantibody 
 titers. Drawing parallels from the literature on auto-
immune hepatitis, the authors coined the term ‘auto-
immune pancreatitis’ (AIP)  [3] to describe this clinical 
entity. In 2002, the Japan Pancreas Society proposed di-
agnostic criteria for AIP  [4] based on the classic imaging 
and serologic findings; these were revised in 2006  [5] .
 In 2001, Hamano et al.  [6] reported from Japan that 
elevated serum IgG4 levels were highly specific and sensi-
tive for the diagnosis of AIP. In 2003, Kamisawa et al.  [7] 
suggested that AIP is a systemic disease, based on the 
findings that there is abundant infiltration of the pan-
creas and other involved organs with IgG4-positive plas-
ma cells. These features were included in the Korean di-
agnostic criteria for AIP proposed in 2007  [8] . In 2008, 
Japanese and Korean societies agreed on Asian consensus 
criteria for the diagnosis of AIP  [9] . Recently, a Japanese 
study based on a survey of 17 centers in Japan identified 
563 patients with AIP in Japan  [10] .
 Meanwhile, reports from Europe and the USA have 
described unique histologic patterns in resected pancre-
ata of patients with mass-forming, chronic, nonalcoholic 
pancreatitis, showing clinical and histopathologic fea-
tures overlapping with those of Japanese patients. In the 
first European study published in 1997, Ectors et al.  [11] 
described the histologic pattern of ‘non-alcoholic duct 
destructive pancreatitis’ in 12 cases of idiopathic chronic 
pancreatitis, a histologic pattern which was clearly distin-
guishable from that of alcoholic chronic pancreatitis. The 
authors noted similarity of the pancreatic histopatholog-
ic findings not only with those reported in association 
with ulcerative colitis by Ball et al.  [12] from the Mayo 
Clinic in 1950, but also with pancreatic involvement seen 
in sclerosing cholangitis reported from Japan  [2] , as noted 
above. Italian diagnostic criteria for AIP were reported in 
2003  [13] and were based on the histologic hallmarks out-
lined in the article by Ectors et al.  [11] .
 In 2003, the Mayo Clinic group in the USA reported 
35 cases of ‘idiopathic chronic pancreatitis with lympho-
plasmacytic infiltration, sometimes called autoimmune 
pancreatitis’  [14] . They observed 2 distinct histologic pat-
terns in these patients: (1) LPSP and (2) idiopathic duct-
centric pancreatitis (IDCP). LPSP resembled Japanese de-
scriptions of histology seen in AIP, and IDCP resembled 
the European descriptions of ‘duct-destructive pancre-
atitis’. The authors noted an overlap between the histo-
logic features of the 2 patterns. They did not speculate on 
the etiology of IDCP, but wondered if LPSP was of auto-
immune etiology. In 2006, Mayo Clinic investigators out-
lined diagnostic criteria for AIP using clinical data from 
patients with histologically confirmed LPSP  [15] .
 In 2004, Zamboni et al.  [16] described the histology of 
62 patients with ‘autoimmune pancreatitis’ from Europe; 
the unifying histologic feature in all patients was a peri-
ductal lymphoplasmacytic infiltrate with periductal fi-
brosis without any of the features seen in alcoholic pan-
creatitis, namely ductal dilatation or irregularity, calculi 
or pseudocysts. As in the Mayo Clinic series, 2 groups of 
patients were distinguished on the basis of a histological 
criterion that was called a ‘granulocytic epithelial lesion’ 
(GEL). Interestingly, the 2 groups of patients also differed 
with regard to features such as gender, mean age and as-
sociated immune-related diseases.
 Summary: ‘AIP’ has been extensively described in re-
ports from Japan, Europe and the USA. Large series of 
‘AIP’ reported from Japan have been based on a distinct 
clinical phenotype, with little emphasis on or need for 
histology to diagnose the disease. On the other hand, de-
tailed descriptions of at least 2 histopathologic patterns 
in patients with nonalcoholic idiopathic chronic pancre-
atitis, namely LPSP or AIP without GELs and IDCP or 
AIP with GELs, have been reported from Europe and the 
USA. Both histopathologic patterns have been included 
under the term ‘AIP’, based on the presence of features 
common to both, namely periductal lymphoplasmacytic 
infiltration and peculiar periductal fibrosis. The Euro-
pean diagnostic criteria for AIP use the presence of GEL 
as a hallmark of AIP, while criteria from the USA are 
based on clinical features of LPSP. Not surprisingly, the 
clinical phenotypes associated with both these histopath-
ologic patterns have been called AIP.
 The Honolulu Consensus Conference on AIP
 On 4 November, 2009, experts from Japan, Korea, Eu-
rope (UK, Germany, Sweden and Italy) and the USA met 
in Honolulu, Hawaii, to describe the entity of AIP as they 
recognized it. The experts included gastroenterologists, 
pathologists, radiologists and surgeons. The goals of the 
meeting were to (1) agree upon a clinical and histological 
definition of AIP, (2) determine if the descriptions of the 
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disease from Japan, Europe and USA refer to 1 or more 
disease entities and (3) arrive at a consensus on diagnos-
tic criteria for AIP. In this review, the deliberations of the 
expert panel regarding the first 2 questions are detailed. 
During the deliberations, which were in a question and 
answer format, the questions shown below were dis-
cussed. The document was subsequently revised by the 
participants.
 Definition of AIP
 Question: Can AIP Be Distinguished from Other 
Forms of Chronic Pancreatitis Based on Histologic 
Features in Resected Pancreata?
 At the Honolulu Consensus Conference on AIP, pre-
liminary data were presented from an international con-
cordance study of 40 resected cases of chronic pancreati-
tis to determine if AIP can be distinguished from alco-
holic and obstructive forms of chronic pancreatitis. This 
study is ongoing. While the interobserver variability was 
moderate for the group as a whole, data from the 5 most 
accurate reviewers demonstrated 91.2% sensitivity and 
98% specificity. The kappa statistic for the 5 readers was 
0.89, reflecting excellent interobserver agreement. These 
findings suggest the need for additional educational ef-
forts to improve the overall performance among patholo-
gists. Full results of this study will be published shortly.
 Summary: The expert panel agreed that AIP has 
unique histopathologic features which allow it to be dis-
tinguished from other forms of chronic pancreatitis.
 Question: Is There More than One Histopathologic 
Subtype of AIP?
 In the concordance study noted above, readers were 
asked to classify the histologic patterns seen in AIP as ei-
ther LPSP or IDCP. The sensitivity and specificity among 
the top 5 readers was 84 and 76.4%, respectively, with a 
kappa of 0.59, reflecting moderate interobserver agree-
ment. Some readers had not previously diagnosed both 
histologic patterns and chose not to subdivide AIP into 
LPSP and IDCP, underscoring the need for additional ed-
ucational efforts to improve the overall performance 
among pathologists.
 Table 1. C omparison of the histology of LPSP (fig. 1), IDCP (fig. 5) and alcoholic chronic pancreatitis
LPSP (AIP without GELs) IDCP (AIP with GELs) Alcoholic chronic pancreatitis
General
description
fibroinflammatory process involving 
pancreatic ducts, lobules, veins and 
common bile duct, easily recognized on 
low-power view 
fibroinflammatory process involving mainly 
pancreatic ducts and also the intrapancreatic 
common bile duct, but less marked in lobules 
and veins
dilated and irregularly shaped
medium-sized and large ducts commonly 
containing calculi; perilobular and 
patchy intralobular fibrosis with usually 
sparse inflammation
Infiltrate predominantly lymphoplasmacytic
infiltration often with eosinophils and
rare neutrophils 
predominantly lymphoplasmacytic
infiltration;  neutrophilic infiltration of
medium-sized and small ducts and often acini
sparse infiltrates of lymphocytes, plasma 
cells and macrophages
Pancreatic
ducts
dense periductal inflammation without 
epithelial damage; lumina of the ducts
are patent
dense periductal inflammation associated
with destruction of the duct epithelium
by neutrophilic granulocytes (GEL) 
enlarged and distorted ducts, rarely 
surrounded by an inflammatory 
infiltrate
Intraductal protein
plugs and stones
no no frequent
Lobules lymphoplasmacytic infiltration involving 
and replacing acinar tissue
patchy lymphoplasmacytic infiltration, 
commonly admixed with neutrophils 
patchy lobular atrophy with fibrosis and 
sparse mononuclear cell infiltration
Veins obliterative phlebitis (organized 
obstruction of veins in association with 
dense lymphoplasmacytic infiltration)
obliterative phlebitis rarely seen no obliterative phlebitis 
Arteries intense arterial involvement rarely seen arterial involvement usually absent no arterial involvement
Pseudocysts no no yes
Peripancreatic fat fibroinflammatory process may extend
to peripancreatic region
inflammation usually limited to the pancreas peripancreatic fat necrosis and
pseudocysts frequent
IgG4 immuno-
staining
abundant (>10 cells/high-power field) 
IgG4-positive cells
scant to no IgG4-positive cells scant to no IgG4-positive cells
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 Question: What Are the Histologic Diagnostic 
Criteria for LPSP and IDCP?
 In response to this question, expert pathologists agreed 
on the following ( table 1 ):
 LPSP (AIP without GELs) has 3 essential histologic 
features ( fig. 1 )  [14, 17] : (1) a lymphoplasmacytic infil-
trate surrounding small interlobular pancreatic ducts 
that does not destroy the pancreatic ductal epithelium; 
(2) a swirling fibrosis centered around ducts and veins 
(storiform fibrosis;  fig.  2 ) but most prominent in the 
peripancreatic adipose tissue, and (3) obliterative phlebi-
tis, wherein the infiltrate surrounds and obliterates pan-
 Fig. 1. LPSP. Low-power view showing 
periductal lymphoplasmacytic infiltrate 
(circle), storiform fibrosis with inflamma-
tory cellular stroma and obliterative phle-
bitis (arrow). Note the intact ductal epithe-
lium without inflammation. 
 Fig. 2. Storiform fibrosis showing delicate 
short collagen bands randomly interlacing 
in every direction and intermixing with 
inflammatory cells as well as fibroblasts. 
  Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e  
  Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e  
 Chari et al. Pancreatology 2010;10:664–672668
creatic veins ( fig.  3 ). Destructive changes in the ducts 
and acini caused by infiltrating granulocytes are typi-
cally absent. Immunostaining reveals abundant ( 1 10 
cells/high-power field) IgG4-positive cells ( fig.  4 )  [18, 
19] .
 IDCP (AIP with GELs) has a histologic pattern dis-
tinct from LPSP  [2, 14, 17] , though it also shares some 
features with LPSP.  Periductal  lymphoplasmacytic infil-
trate  is seen in both forms of AIP. Diffuse inflammation 
and diffuse storiform fibrosis as well as obliterative 
phlebitis, which are characteristic of LPSP, are less 
prominent in IDCP ( fig. 5 ). The most distinctive feature 
of IDCP is the presence of GELs, seen in medium-sized 
and small ducts and also often in the acini ( fig. 6 ), chang-
es that may lead to the destruction and obliteration of 
the duct lumen  [14, 17] . The other distinctive feature is 
the scanty presence ( ! 10 cells/high-power field) or com-
plete absence of IgG4-positive plasma cells on immu-
nostaining.
 Question: Do LPSP and IDCP Have Distinct Clinical 
Profiles?
 Data were presented from Europe and the USA, based 
on histologically confirmed cases of LPSP and IDCP, 
highlighting differences in the demography, clinical pre-
sentation, serology, involvement of other organs and dis-
ease relapse ( table 2 ).
 Summary: The participants agreed that patients cur-
rently diagnosed with ‘AIP’ have 2 histopathologically 
distinct types of disease that are associated with distinct 
clinical profiles. Thus, it is possible that LPSP (AIP with-
out GELs)  and IDCP (AIP with GELs) are histopatho-
logic correlates of 2 distinct forms of AIP.
 Fig. 3. Obliterative phlebitis (oval). Dense 
peri- and intravenular inflammatory infil-
trate with fibrosis destroying the endothe-
lium and obliterating the lumen. Note that 
the neighboring artery (arrow) is spared. 
  Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e  
 Fig. 4. IgG4 immunostain in LPSP shows markedly increased 
( 1 30/high-power field) periductal IgG4+ plasma cell infiltrate. 
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 Question: Are There Geographic Differences in the 
Proportion of AIP Cases Identified as LPSP or IDCP?
 The diagnosis of LPSP and IDCP requires histopatho-
logic examination, which is not frequently available. 
Based on data presented at the meeting, there are only a 
very small number of histologically confirmed IDCP cas-
es in Japan. Over 500 cases of AIP with a clinical profile 
resembling that seen in subjects with LPSP have been re-
ported from Japan. In contrast, in the USA and in most 
centers in Europe (Germany, Sweden, Italy), both types of 
AIP, i.e. LPSP (AIP without GELs) and IDCP (AIP with 
GELs), are observed. Reports from London, UK, suggest 
a predominantly LPSP-like profile of AIP. A Mayo Clinic 
series had 78 patients with an LPSP-like clinical profile 
and 19 with an IDCP-like clinical profile. A series of 88 
patients from Germany, Italy and Belgium who were 
treated by pancreatic resection showed a predominance 
of LPSP (60%) over IDCP (40%).
 Summary: The proportion of LPSP versus IDCP 
among patients diagnosed with AIP varies substantially 
among centers across the world. Whether this reflects a 
true geographic difference in the incidence of these 2 
forms of AIP is not yet clear.
 Question: Should the Clinical Phenotypes Associated 
with LPSP and IDCP Be Referred to as Type 1 and 
Type 2 AIP?
 This question sparked a vigorous debate. The center of 
the controversy related to the use of the term ‘autoim-
mune’ for IDCP. The Japanese experts contended that 
there is strong evidence to suggest that LPSP is an auto-
immune disorder [hypergammaglobulinemia, preva-
lence of autoantibodies (albeit nonspecific) and a steroid-
 Fig. 6. GEL in IDCP. Periductal and intraepithelial neutrophilic 
infiltrate destroying the ductal epithelium, often with intralumi-
nal microabscesses. 
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 Fig. 5. GEL-positive AIP or IDCP. Low-
power view showing periductal lympho-
plasmacytic and neutrophilic infiltrate 
with intraepithelial inflammation and de-
struction of small ducts and ductal epithe-
lium (solid arrows), as well as lobular lym-
phoplasmacytic and neutrophilic infil-
trate (dashed arrows). Note that the 
storiform fibrosis is not as prominent as 
that in LPSP. 
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responsive lymphoplasmacytic infiltrate], while IDCP 
lacks such evidence. They believed that because of the 
relative paucity of data concerning IDCP, it was prema-
ture to label it as an autoimmune disorder. They further 
noted that unlike LPSP, which is commonly associated 
with extrapancreatic manifestations, IDCP appears to 
occur in isolation, except for a potential association with 
inflammatory bowel disease, particularly ulcerative 
 colitis.
 Others contended that the 2 diseases had many simi-
larities. The most common clinical presentation of both 
diseases is obstructive jaundice with a pancreatic en-
largement/mass. However, in the AIP patients with LPSP 
(unlike in IDCP), obstructive jaundice is caused by the 
specific pathologic change, i.e. sclerosing cholangitis 
with similar pathological features to LPSP. The few pan-
creatograms from IDCP cases that were shown during 
the meeting were not distinguishable from those seen in 
LPSP. Also, IDCP is also associated with a periductal 
lymphoplasmacytic infiltrate and storiform fibrosis, 
though to a lesser extent than LPSP. In fact, in the con-
cordance study, many pathologists could not distinguish 
LPSP from IDCP. Finally, IDCP is also steroid responsive. 
Many experts believed therefore that IDCP may be an 
organ (pancreas)-specific autoimmune disorder. Howev-
er, the occurrence of neutrophils infiltrating some ducts 
and acini so far remains unexplained by an autoimmune 
mechanism.
 At least some experts believe that the overlap between 
the 2 forms of AIP is further confounded by the fact that 
IDCP and LPSP may not always be distinguishable using 
current diagnostic criteria. For example, both can fulfill 
Japanese and Asian diagnostic criteria for AIP based on 
imaging criteria and biopsy showing lymphoplasmacytic 
infiltrate with fibrosis, histologic features common to 
both LPSP and IDCP. Similarly, with the Italian criteria 
such patients would fulfill the criteria for AIP if they re-
sponded to steroids, as both forms of the disease do. Sim-
ilarly, clinicians have used a steroid trial for the diagnosis 
of AIP using HISORt (histology, imaging features, serol-
ogy, other organ involvement and response to steroid 
treatment) criteria, though collateral evidence of AIP in 
the form of raised serum IgG4 or other organ involvement 
(features of LPSP) is necessary before steroids are given. A 
case of AIP from Japan was presented which resembled 
IDCP with regard to the clinical profile (young, seronega-
tive and associated with inflammatory bowel disease) but 
met the Japanese/Asian diagnostic criteria noted above. A 
histologically confirmed case of IDCP from Korea was 
presented whose imaging features resembled those seen in 
LPSP and which responded dramatically to steroids with 
normalization of imaging abnormalities.
 The expert panel acknowledged that the current prac-
tice is to refer to both disease entities as AIP due to the 
inability to differentiate LPSP from IDCP without histol-
ogy and review by an experienced pathologist. Therefore, 
there is a clear need to distinguish these entities noso-
logically to avoid continued confusion between them, to 
help provide prognostic information and to guide patient 
care. This would also provide the framework for future 
research in the field, including identification of specific 
biomarkers for both entities.
 The European and American experts favored the con-
tinued inclusion of IDCP as a unique type of AIP due to 
 Table 2. C linical profiles of LPSP (AIP without GELs) and IDCP (AIP with GELs)
 Clinical feature  German series  U SA (Mayo Clinic) series [22] 
 GEL –ve (n = 55)  GEL +ve (n = 33)  LPSP ( n = 78)  IDCP (n = 19) 
 Mean age, years  62  48  61.8 8 14.2  47.7 8 18.8 
 Male, %  61  48  77  74 
 Serum IgG4  47/59 (80%)  1/6 (17%) 
 Other organ involvement  sialadenitis, retroperitoneal
 fibrosis, interstitial nephritis 
 none  proximal biliary stenosis,
 sialadenitis, retroperitoneal
 fibrosis, interstitial nephritis 
 none 
 Inflammatory bowel disease  absent  present  5 (6%)  3 (16%) 
 Relapse  biliary  present  55% (biliary, retroperitoneum
 most common) 
 none 
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 Appendix
 Names, specialties and affiliations of the Autoimmune Pancreatitis International Cooperative Study Group members (in alphabetical 
order)
Name Specialty Affiliation
Suresh T. Chari, MD Internal Medicine/Gastroenterology Mayo Clinic College of Medicine, Rochester, Minn., USA
Carlos Fernandez del Castillo, MD Surgery Massachusetts General Hospital, Boston, Mass., USA
Vikram Deshpande, MD Pathology Massachusetts General Hospital, Boston, Mass., USA
Martin L. Freeman, MD Internal Medicine/Gastroenterology University of Minnesota, Minn., USA
Luca Frulloni, MD, PhD Internal Medicine/Gastroenterology University of Verona, Verona, Italy
Timothy B. Gardner, MD Internal Medicine/Gastroenterology Dartmouth Medical School, Lebanon, N.H., USA
Vay Liang William Go, MD Internal Medicine/Gastroenterology University of California Los Angeles, Los Angeles, Calif., USA
Atsushi Irisawa, MD, PhD Internal Medicine/Gastroenterology Fukushima Medical University School of Medicine, Fukushima, Japan
Tetsuhide Ito, MD, PhD Internal Medicine/Gastroenterology Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
Terumi Kamisawa, MD, PhD Internal Medicine/Gastroenterology Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
Shegiyuki Kawa, MD, PhD Internal Medicine/Gastroenterology Shinshu University, Japan
Okazaki Kazuichi, MD, PhD Internal Medicine/Gastroenterology Kansai Medical University, Osaka, Japan
Myung-Hwan Kim, MD, PhD Internal Medicine/Gastroenterology University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
Guenter Kloeppel, MD Pathology University of Kiel, Kiel, Germany
Motohiro Kojima, MD Pathology National Cancer Center Hospital, Chiba, Japan
Markus M. Lerch, MD Internal Medicine/Gastroenterology Klinikum der Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany
Michael J. Levy, MD Internal Medicine/Gastroenterology Mayo Clinic College of Medicine, Rochester, Minn., USA
Matthias Lohr, MD Internal Medicine/Gastroenterology Karolinska Institute, Stockholm, Sweden
Daniel S. Longnecker, MD Pathology Dartmouth Medical School, Lebanon, N.H., USA
Mari Mino-Kenudson, MD Pathology Massachusetts General Hospital, Boston, Mass., USA
Nobumasa Mizuno, MD Pathology Aichi Cancer Center Hospital, Nagoya, Japan
Kenji Notohara, MD, PhD Pathology Kurashiki Central Hospital, Kurashiki, Japan
Manuel Rodriguez-Justo, MD Pathology University College London Hospitals, London, UK
Tooru Shimosegawa, MD, PhD Internal Medicine/Gastroenterology Tohoku University Graduate School of Medicine, Sendai, Japan
Thomas C. Smyrk, MD Pathology Mayo Clinic College of Medicine, Rochester, Minn., USA
Amitabh Srivastava, MD Pathology Dartmouth Medical School, Lebanon, N.H., USA
Aravind Sugumar, MD Internal Medicine/Gastroenterology Mayo Clinic College of Medicine, Rochester, Minn., USA
Naoki Takahashi, MD Radiology Mayo Clinic College of Medicine, Rochester, Minn., USA
George Webster, MD, FRCP Internal Medicine/Gastroenterology University College London Hospitals, London, UK
Giuseppe Zamboni, MD Pathology University of Verona, Verona, Italy
Yoh Zen, MD Pathology King’s College Hospital, London, UK
Lizhi Zhang, MD Pathology Mayo Clinic College of Medicine, Rochester, Minn., USA
the similar clinical presentations, overlapping diagnostic 
criteria (including histology) and similar response to ste-
roid administration. The terms type 1 and type 2 AIP 
have recently been introduced into the literature to refer 
to the clinical profiles associated with LPSP and IDCP, 
respectively,  [20–22] . Most, but not all present at the 
meeting agreed that this terminology best reflected our 
current state of knowledge. All agreed that as we learn 
more about both entities, the terminology would surely 
change.
 Summary: (1) Diagnostic criteria for AIP should rec-
ognize that there are 2 forms of the disease. This will al-
low further study of these entities and identification of 
specific markers for both forms of AIP.
 (2) Currently, the disease associated with IDCP can be 
definitively diagnosed only by histologic examination. 
Use of a steroid trial does not distinguish the disease as-
sociated with LPSP from IDCP.
 (3) While uniform consensus was not achieved, the 
majority of experts agreed that the clinical phenotypes 
associated with the histopathologic patterns of LPSP 
(AIP without GELs) and IDCP (AIP with GELs) should 
be referred to as type 1 and type 2 AIP, respectively.
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